본문 바로가기
KERD
논문KCI 등재

대사증후군과 뇌졸중

Metabolic Syndrome and Stroke

김용재
대한신경과학회 (Korean Neurological Association)|2005.10|대한신경과학회지 (Journal of the Korean Neurological Association)|제23권 제5호|pp. 585-594

1

조회

0

다운로드

11

인용

0

참고문헌

주제분류신경과학

초록

대사증후군은 뇌졸중을 포함한 심혈관 질환의 위험도를 증가시킨다. 또한 뇌졸중 환자의 상당수는 대사증후군을 가지고 있다. 뇌졸중 환자에서 대사증후군의 높은 유병률은 대사증후군을 적극적인 조절과 치료를 필요로 하는 대상으로 만들었다. 뇌졸중의 예방을 위해서는 생활 습관의 변화를 근간으로 한 치료 외에, 스타틴제제나 안지오텐신전환효소억제제, 인슐린 감수성 개선제 및 항혈전제를 사용한 대사증후군 구성 요소들에 대한 전반적인 그리고 적극적인 치료가 요구된다. 특히 스타틴제제는 대사증후군에서 흔한 이상지질혈증을 교정할 뿐 아니라 비지질 위험인자들에도 영향을 미쳐, 뇌졸중의 예방과 조절에 유용한 역할을 할 것으로 기대한다.

Abstract

Metabolic syndrome, comprising of abdominal obesity, elevated triglyceride levels, low levels of high-density lipoprotein cholesterol, elevated blood pressure, and impaired glucose metabolism, greatly increases the risk of cardiovascular disease, including stroke. The high prevalence of metabolic syndrome among individuals who experience stroke makes the metabolic syndrome a target for aggressive intervention and therapy. Primary intervention for stroke focuses on achievement of a healthy body weight and regular physical activity to prevent or correct dyslipidemia, insulin resistance, and high blood pressure. Statins favorably affect both lipid and nonlipid risk factors for stroke, making them a useful tool for stroke prevention.

참고문헌 (54)

  1. "2001년 사망원인통계결과" (2002), 통계청
  2. Reaven GM, "Banting lecture 1988.Role of insulin resistance in human disease", 37, pp.1595~1607 (1988)
  3. DeFronzo RA, "A multifaceted syndrome responsible for NIDDM"
  4. Cameron AJ, "The metabolic syndrome:prevalence in worldwide populations", 33, pp.351~375 (2004)
  5. Himsworth HP, "Diabetes mellitus:its differentiation into insulin- sensitive and insulin-insensitive types", i, pp.127~130 (1936)
  6. Yalow RS, "Immunoassay of endogenous plasma insulin in man", 39, pp.1157~1175 (1960)
  7. Alberti KG, "diagnosis and classification of diabetes mellitus and its complications diagnosis and classification of diabetes mellitus provisional report of a WHO consultation", pp.539~553
  8. "Executive Summary of The Third Report of The National Cholesterol Education Program Expert Panel on Detection And Treatment of High Blood Cholesterol In Adults", pp.2486~2497 (2001)
  9. World Health Organization, "The Asia- Pacific Perspective" (2000)
  10. Balkau B, "Comment on the provisional report from the WHO consultation European Group for the Study of Insulin Resistance", pp.442~443 (1999)
  11. Aronne LJ, "Classification of obesity and assessment of obesity- related health risks", 10 suppl 2, pp.105~115 (2002)
  12. Ford ES, "Prevalence of the metabolic syndrome among US adults:findings from the third National Health and Nutrition Examination Survey", 287, pp.356~359 (2002)
  13. Park HS, "Prevalence and associated factors with metabolic syndrome in South Korea-from the Korean National Health and Nutrition Examination Survey 1998- Journal of Korean Society for the Study of Obesity 2003", pp.1~14
  14. Cho HK, "Handbook of Atherosclerosis and Lipid metabolism", pp.238~318 (2004), Jin Publishing & Printing Co
  15. Stern MP, "Identification of persons at high risk for type 2 diabetes mellitus", pp.575~581
  16. Klein BE, "Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam", 25, pp.1790~1794 (2002)
  17. Lakka HM, "The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men", 288, pp.2709~2716 (2002)
  18. van der Graaf Y, "The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease peripheral arterial disease or abdominal aortic aneurysm", pp.342~348
  19. Kim YJ, "Carotid intima-media thickness in healthy koreans Is it also useful in cerebrovascular risk assessment in intracranial disease prone population", pp.13~4
  20. Brunzell JD, "Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus", 115 suppl 8a, pp.24~28 (2003)
  21. Steinmetz A, "Treatment of dyslipoproteinemia in the metabolic syndrome", pp.548~559
  22. Packard CJ, "LDL subfractions and atherogenicity:an hypothesis from the University of Glasgow", 13, pp.379~390 (1996)
  23. Pyorala M, "Hyperinsulinemia and the risk of stroke in healthy middle-aged men.The 22 year follow-up results of the Helsinki Policemen Study", 29, pp.1860~1866 (1998)
  24. Folsom AR, "Prospective associations of fasting insulin,body fat distribution,and diabetes with risk of ischemic stroke", 22, pp.1077~1083 (1999)
  25. Kernan WN, "Insulin resistance and risk of stroke", 59, pp.809~815 (2002)
  26. Gorelick PB, "Stroke prevention therapy beyond antithrombotics:unifying mechanisms in ischemic stroke pathogenesis and implications for therapy", 33, pp.862~875 (2002)
  27. Ishizaka N, "Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals", 28, pp.27~34 (2005)
  28. Scott CL, "Diagnosis,prevention,and intervention for the metabolic syndrome", 92 suppl 1a (2003)
  29. Schiffrin EL, "Multidisciplinary Research Group on Hypertension", pp.15 115~1 122, Beyond blood pressure
  30. Benfante R, "Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men.Implications of shared risk", 25, pp.814~820 (1994)
  31. Rexrode KM, "A prospective study of body mass index,weight change,and risk of stroke in women", 277, pp.1539~1545 (1997)
  32. Suk SH, "Abdominal obesity and risk of ischemic stroke:the Northern Manhattan Stroke Study", 34, pp.1586~1592 (2003)
  33. Aubert H, "Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome", 1, pp.791~797 (2003)
  34. Bajaj M, "Type 2 diabetes in South Asians:a pathophysiologic focus on the Asian-Indian epidemic", 4, pp.213~218 (2004)
  35. Gil-Nunez AC, "Advantages of lipid lowering therapy in cerebral ischemia:role of HMG CoA reductase inhibitors", 11 suppl 1, pp.85~95 (2001)
  36. Ninomiya JK, "Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey", 109, pp.42~46 (2004)
  37. Cho HJ, "The clustered metabolic risk factors among patient with ischemic stroke-A preliminary study", 5 (2003)
  38. Lindstrom J, "The Finnish Diabetes Prevention Study(DPS)Lifestyle intervention and 3-year results on diet and physical activity", 26, pp.3230~3236 (2003)
  39. Gordon NF, "Physical activity and exercise recommendations for stroke survivors an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise the Council on Cardiovascular Nursing the Council on Nutrition", pp.2031~2041
  40. Steinmetz A, "Treatment of dyslipoproteinemia in the metabolic syndrome", pp.~559
  41. Robins SJ, "Insulin resistance and cardiovascular events with low HDL cholesterol", pp.1513~1517, Faas FH
  42. Avema M, "Statins and metabolic syndrome", 1253, pp.283~246 (2003)
  43. Bedi A, "How do HMG-CoA reductase inhibitors prevent stroke?", pp.7~14 (2002)
  44. Kim YJ, "Use of statin and angiotensin converting enzyme inhibitor in stroke prevention", 7, pp.39~45 (2005)
  45. Amarenco P, "Statins for stroke prevention:disappointment and hope", 109, pp.44~49 (2004)
  46. Scandinavian Simvastatin Survival Study Group, "Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease", pp.1383~1389
  47. Heart Protection Study Collaborative Group, "MRC", BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, lancet2002, 7~22
  48. Sever PS, "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations", pp.1149~1158 (2003)
  49. Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS)multicentre randomised placebo-controlled trial", 364, pp.685~696 (2004)
  50. Knowler WC, "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", 346, pp.393~403 (2002)
  51. Durbin RJ, "Thiazolidinedione therapy in the prevention", delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance, 2004, pp.6, 280~285
  52. Chiasson JL, "Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial", 290, pp.486~494 (2003)
  53. Chobanian VA, "The Seventh Report of the Joint National Committee on Prevention and Treatment of High Blood Pressure", pp.2560~2571
  54. American Diabetes Association, "Prevention or delay of type 2 diabetes.Clinical Practice Recommendations 2004", 27, pp.47~53 (2004)

관련 논문AI추천

일개 대학병원에 내원한 뇌경색 환자와 정상인에서 대사증후군 유병률 비교강정묵대한뇌졸중학회 · 대한뇌졸중영문학회지2005 · 제7권 제1호Stroke Update 2009: 뇌졸중의 위험인자 및 일차 예방박종무대한뇌졸중학회 · 대한뇌졸중영문학회지2009 · 제11권 제2호뇌졸중 이후의 이상지혈증의 관리송태진, 장윤경대한신경과학회 · 대한신경과학회지2022 · 제40권 제3호Stroke Update: 위험인자 및 일차예방김재국, 이수주대한뇌졸중학회 · 대한뇌졸중영문학회지2012 · 제14권 제1호허혈성 뇌졸중 환자에서 대사증후군과 호모시스테인의 관계박종호, 박현미, 신동진, 신원철, 이영배대한신경과학회 · 대한신경과학회지2005 · 제23권 제1호뇌졸중 일차예방을 위한 최신 과학적 근거(2011): 이상지질혈증과 염증강규식, 구자성, 권순억, 김한영, 나정호, 박종무, 배희준, 오창완, 유경호, 윤병우, 이병철, 정진상, 조용진, 한상원, 허지회, 홍근식대한신경과학회 · 대한신경과학회지2012 · 제30권 제3호

이 간행물의 다른 논문 (18건)

MTHFR C677T 유전자 다형성과 허혈성 뇌졸중의 상관 관계김숙희, 이정화, 윤지영, 최병옥, 박기덕, 최경규, 조현지, 김희진, 김지영pp. 607-613피질하 혈관성 치매와 알쯔하이머병에서 신경심리학적 평가의 차이김재우, 김종국, 차재관, 박민정, 박경원, 김상호, 천상명pp. 614-620저주파 반복적 경두개자기자극술 후 신경활성도의 변화박기덕, 조현지, 이민아, 이향운, 최경규, 김희진pp. 627-6343차원 보행분석시스템을 이용한 파킨슨병 환자의 보행 분석이승화, 박건우, 이대희, 고성범, 조승철, 윤준식, 홍성규pp. 635-641수근관증후군에서 수부 정중운동신경검사 및 정중-척골신경 잠복기 차이의 비교김현영, 백원기, 고성호, 김주한, 김승현, 김희태, 이영주, 이규용pp. 650-654
원문 보기